Century Therapeutics, Inc. - Common Stock (IPSC)

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

While not on everyone’s radar, these enticing entities just might deliver the goods.

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.

Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps & Tech-heavy QQQ ETF by 11.4% (MTD)

Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler.

Why Are Gamma-Delta T Cells Important In Fighting Cancer?